AYTU — AYTU BIOPHARMA, INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1385818 ·
Last close
$2.05
Market Cap
$22.28M
52W High
$3.07
52W Low
$1.80
ADV30
41,441
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 16,106,000 | 10,409,000 | -777,000 | -15,000 | 105,007,000 | 26,308,000 | 69,733,000 |
| Mar 2026 | 12,411,000 | 7,599,000 | -4,064,000 | -5,618,000 | 111,689,000 | 26,715,000 | 76,546,000 |
| Dec 2025 | 15,165,000 | 9,624,000 | -1,970,000 | -10,584,000 | 122,000,000 | 30,025,000 | 107,799,000 |
| Sep 2025 | 13,888,000 | 9,186,000 | -1,504,000 | 1,965,000 | 124,988,000 | 32,630,000 | 101,817,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$3,281,000
Investing CF
$-29,000
Financing CF
$-7,896,000
CapEx
$-3,104,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.66
As of
2026-09-27
Balance + Analyst (yfinance extras)
Retained Earnings
$-347,787,000
Inventory
$6,860,000
Receivables
$22,779,000
ST Investments
—
EBIT TTM
$-12,336,000
Pretax Income TTM
$-14,231,000
Interest Exp TTM
$1,895,000
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$57,570,000
EBITDA
$-4,385,000
Free Cash Flow
$5,597,750
Enterprise Value
$16,574,094
Total Cash
$26,308,000
Total Debt
$18,106,000
Shares Out
10,866,708
Trailing EPS
$-1.16
Book Value
$3.27
ROE
-52.6%
ROA
-4.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 57,570,000 | -8,315,000 | -14,252,000 | 105,007,000 | 69,733,000 | 35,274,000 | 3,281,000 |
| Jun 2025 | 66,382,000 | 2,537,000 | -13,562,000 | 124,177,000 | 105,211,000 | 18,966,000 | -1,937,000 |
| Jun 2024 | 65,183,000 | 565,000 | -15,844,000 | 118,095,000 | 90,379,000 | 27,716,000 | -1,388,000 |
| Jun 2023 | 107,399,000 | -12,329,000 | -17,051,000 | 136,463,000 | 97,106,000 | 39,357,000 | -5,129,000 |
TTM Snapshot
Revenues TTM
$56,599,000
NetIncome TTM
$-34,055,000
OpCashFlow TTM
—
Assets (Latest)
$111,689,000
Forward EPS
$0.17
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MCUJF | MEDICURE INC | $21.92M | $2.10 | — |
| TXMD | TherapeuticsMD, Inc. | $23.26M | $2.01 | — |
| OPTH | Optimi Health Corp. | $23.39M | $4.09 | — |
| JAGX | Jaguar Health, Inc. | $23.41M | $4.53 | — |
| PVCT | PROVECTUS BIOPHARMACEUTICALS, INC. | $21.01M | $0.05 | — |
News headlines (Yahoo Finance, 1h cache)
Elite Pharmaceuticals vs. Aytu: Which CNS Stock Is the Better Buy?
2026-10-07 15:08 · Yahoo
Aytu BioPharma Inc (AYTU) (Q4 2026) Earnings Call Highlights: EXXUA Launch Accelerates as ...
2026-09-23 05:00 · Yahoo
Aytu BioPharma, Inc. (AYTU) Reports Q4 Loss, Beats Revenue Estimates
2026-09-22 21:15 · Yahoo
Aytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results
2026-09-22 20:05 · Yahoo
Aytu BioPharma to Report Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results on September 22, 2026
2026-09-16 20:30 · Yahoo
Aytu BioPharma to Present at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17, 2026
2026-06-01 20:15 · Yahoo
Aytu (AYTU) Q3 2026 Earnings Transcript
2026-05-13 21:54 · Yahoo
Aytu BioPharma Reports Fiscal 2026 Third Quarter Operational and Financial Results
2026-05-13 20:05 · Yahoo
Full Transcript: Aytu BioPharma Q3 2026 Earnings Call
2026-05-13 21:39 · Yahoo
Aytu BioPharma Inc (AYTU) Q3 2026 Earnings Call Highlights: Strong Exua Adoption Amid Revenue ...
2026-05-14 05:02 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.